Statement of Principles concerning chloracne (Reasonable Hypothesis) (No. 62 of 2020)

The central concept is the "reasonable hypothesis" standard itself, which is imported by reference to the VEA and MRCA but is not defined in this instrument. The instrument operates on the premise that the Repatriation Medical Authority has determined that there is sound medical-scientific evidence indicating that chloracne and death from chloracne can be related to relevant service. The second key concept is the definition of chloracne provided in subsection 7(2). It is a chronic skin disease characterised by an acne-like eruption of open and closed comedones (whiteheads and blackheads), pustules and epidermal cysts, occurring after the systemic absorption of certain polyhalogenated aromatic hydrocarbons. The definition expressly excludes drug-related acneiform facial eruptions. This exclusion is important because it prevents claims based on acne-like rashes caused by medications or other non-chloracne agents from being mistaken for the compensable condition. The instrument also defines "death from chloracne" to include death from a terminal event or condition that was contributed to by the person's chloracne. The "terminal event" definition lists five proximate causes: pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function. The third major concept is the "specified list of polyhalogenated aromatic hydrocarbons", which is an exhaustive list set out in the Schedule 1 dictionary. This list includes azobenzenes, azoxybenzenes, o-dichlorobenzene, polybrominated biphenyls (PBBs), polybromodibenzofurans, polychlorinated biphenyls (PCBs), polychlorodibenzofurans (PCDFs) as specified (with detailed congeners), polychlorodibenzo-para-dioxins (PCDDs) as specified (with detailed congeners), polychloronaphthalenes (including specific examples), polychromonaphthalenes, and triazoloquinoxalines. Only exposure to substances on this list can satisfy factors 9(1) and 9(2). The instrument also distinguishes between "clinical onset" and "clinical worsening": factor 9(1) deals with onset, factor 9(2) deals with worsening, and the temporal window for both is three months before the relevant event. Factor 9(3) is the special case of inability to obtain appropriate clinical management for chloracne. "Relevant service" is defined by reference to six categories: operational service, peacekeeping service, hazardous service, and British nuclear test defence service under the VEA, and warlike and non-warlike service under the MRCA. These categories determine which claims are subject to the reasonable hypothesis standard. Finally, section 11 incorporates by reference any other Statement of Principles that covers an injury or disease that is itself a factor under section 9, so that the chain of causation can extend to secondary conditions.

This instrument directly affects any person who has rendered relevant service as defined and who makes a claim for chloracne or death from chloracne under the VEA or the MRCA. That includes veterans of the Australian Defence Force who served in operational, peacekeeping, hazardous, or British nuclear test defence capacities, as well as members of Peacekeeping Forces, and members of the Forces under the VEA, and members under the MRCA who performed warlike or non-warlike service. For those claimants, the instrument determines whether their condition is accepted as service-related under the reasonable hypothesis standard. It also affects dependants who may be eligible for compensation in the event of the veteran's death from chloracne. Indirectly, the instrument affects medical practitioners who must provide evidence about the nature of the skin condition, the timing of exposure, and which polyhalogenated aromatic hydrocarbon was involved. The specificity of the chemical list means that doctors and claimants must be able to identify the exact substance from the specified list, which may require workplace records, environmental testing, or expert opinion. The instrument also affects decision-makers within the Department of Veterans' Affairs and the Veterans' Review Board, who must apply the factors exactly as written and cannot substitute their own medical judgment about whether a different chloracne-causing chemical should qualify. The Repatriation Medical Authority itself is the author of the instrument, but its ongoing role is to review the scientific evidence and potentially revise or repeal the Statement of Principles. The instrument imposes no direct costs on the broader public, but it does create compliance costs for claimants who must gather evidence of exposure, and it influences the allocation of public funds through the compensation system. For businesses that manufactured or used the listed chemicals, there is an indirect effect: if a veteran was exposed during service and later develops chloracne, the resulting compensation claim may ultimately be paid by the Commonwealth, not the business, but the instrument may increase the number of accepted claims and thus increase total compensation expenditure.

The instrument does not itself impose duties on any person. It is a statement of principles that operates as a delegation of legislative power from Parliament to the Repatriation Medical Authority, specifying the medical-scientific criteria that must be satisfied for a reasonable hypothesis to exist. The primary right it recognises is the right of a claimant to have chloracne assessed under the reasonable hypothesis standard if the claimant has rendered relevant service. That right is procedural: it means the decision-maker must apply the factors in section 9 rather than decide the claim on some other basis. The instrument also implies a duty on the Repatriation Medical Authority to base its determination on sound medical-scientific evidence, as stated in section 8, but no enforcement mechanism is provided. The decision-maker has a duty to apply the instrument correctly: they must determine whether at least one factor existed and whether that factor is related to the person's relevant service. If a factor refers to another injury or disease covered by another Statement of Principles, the decision-maker must apply the factors of that other SOP as well, as provided in section 11. The claimant has no duty under the instrument, but they bear the practical burden of producing evidence that meets the requirements. The instrument creates no private rights of action between individuals. It is a public law instrument that governs the relationship between the Commonwealth (through the Department of Veterans' Affairs) and the veteran or member. It also interacts with the duty of the Repatriation Medical Authority to ensure consistency: the instrument repeats the same exposure factor for both onset and worsening, and the same notes, making clear that the standard of proof for both is identical. The instrument distinguishes between pre-service and post-service chloracne: subsection 10(2) provides that factors 9(2) and 9(3) apply only to material contribution to or aggravation of chloracne where the person's chloracne was suffered or contracted before or during (but did not arise out of) the person's relevant service. This preserves the rule that a condition that arose out of service cannot be aggravated by service, but a pre-existing chloracne can be worsened. The instrument does not confer a right to compensation; it merely sets part of the evidentiary test for such a right under the parent Acts.

This instrument contains no penalties, no criminal offences, and no enforcement mechanisms. It is a purely evidentiary and definitional instrument. If a decision-maker fails to apply the Statement of Principles correctly, the claimant may seek review by the Veterans' Review Board or the Administrative Appeals Tribunal, and the error would be a question of law subject to judicial review by the Federal Court. The instrument itself does not create any civil penalties or infringement notices. The only effective enforcement is through the administrative appeals system and the possibility that the Repatriation Medical Authority could be challenged on jurisdictional grounds if it made a determination without sound medical-scientific evidence, but that challenge would be against the instrument itself rather than for breach of it. Because the instrument is made under a specific statutory power, it has the force of law. A decision that fails to apply it could be set aside as ultra vires. The instrument's practical enforcement therefore lies in the hands of claimants and their legal representatives who can argue that a factor was satisfied and the decision-maker did not give it due weight. There is no penalty for a claimant who brings a frivolous claim, although costs may be awarded in some Tribunal proceedings. The instrument also contains no sunset clause or review date, but it can be repealed or replaced by the Repatriation Medical Authority at any time, as indeed this instrument repealed the 2012 version. The lack of penalties is consistent with the character of such statements: they are medical-scientific guidelines given legal force, not regulatory prohibitions. The only sanction for non-compliance by the Authority would be the invalidity of the instrument on judicial review, but that is a constitutional law question outside the scope of the instrument itself.

This instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA). It is a legislative instrument that sits within the broader framework of the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA). Its application is expressly limited to claims to which section 120A of the VEA or section 338 of the MRCA applies. Those sections import the reasonable hypothesis standard for claims relating to certain kinds of service. The instrument therefore does not apply to claims for chloracne that are assessed under the balance of probabilities standard, which applies to safety net claims or claims arising from non-qualifying service. The instrument also interacts with other Statements of Principles. Section 11 provides that if a factor in section 9 refers to an injury or disease that is itself covered by another Statement of Principles (e.g., if a factor requires the existence of a condition like "hepatic porphyria" that has its own SOP), then the factors in that other SOP apply as well. This creates a chain of causation: the chloracne SOP may require proof of exposure to a chemical, but if that chemical exposure causes another disease that then causes chloracne, the other SOP must be satisfied. The instrument also interacts with the common law of causation and with the doctrine of reasonable hypothesis as developed by case law, but no cases are cited in the instrument. The instrument repeals the previous Statement of Principles concerning chloracne No. 17 of 2012. That repeal is effective from the commencement date, so any claim determined after 28 September 2020 must be assessed under the new instrument even if the exposure occurred before that date. The dictionary defines "MRCA" and "VEA" to mean the respective Acts as amended from time to time, so the instrument automatically adapts to future amendments of those Acts. The instrument does not interact with state workers' compensation laws or with the common law tort system, because it is exclusively a federal compensation instrument. It does not affect private rights of action against third parties who may have caused the exposure, such as manufacturers of the listed chemicals. Those actions would be governed by separate tort law and product liability regimes. The instrument also does not directly interact with workplace health and safety legislation, although evidence of exposure collected under such legislation may be relevant.

This instrument is a single edition. It repealed the earlier Statement of Principles concerning chloracne No. 17 of 2012 (F2012L00447). The instrument itself has not been amended since its commencement. It was made on 28 August 2020 and commenced on 28 September 2020. The instrument does not disclose why the 2012 version was replaced, but the reason must relate to a change in the available medical-scientific evidence. The Repatriation Medical Authority has the power under subsection 196B(2) to make new determinations from time to time, and there is no statutory requirement to publicly explain the basis for changes beyond the statement in section 8 that it is of the view that there is sound medical-scientific evidence. The instrument does not provide a retrospective amendment power; it applies only to claims made on or after commencement, though it may apply to claims that were pending at commencement if the decision has not yet been made. The instrument does not contain a provision for automatic review or sunset, so it remains in force until expressly repealed or replaced. Given that the subject matter is a chronic disease caused by specific chlorinated compounds, the science may change as new research emerges about lower dose exposures or different congeners. The previous 2012 version presumably contained a similar list of chemicals and factors, but without access to it we cannot compare the two. The repeal of the earlier instrument means that the 2012 version no longer has any legal effect, and any claim relying on it would be assessed under the new version unless transitional provisions in the VEA or MRCA allow otherwise. No transitional provisions are included in this instrument. The instrument history is therefore minimal, consisting of the original making and the repeal of its predecessor.

This instrument does not cite any litigation history, nor does it refer to any court cases. The instrument is a legislative instrument, not a court decision. However, it is highly likely that the predecessor instrument (No. 17 of 2012) was the subject of review hearings before the Veterans' Review Board and the Administrative Appeals Tribunal, and possibly judicial review in the Federal Court, but no such cases are mentioned. The instrument itself provides the factors that must exist for a reasonable hypothesis, and those factors have been the subject of considerable tribunal and court interpretation in the broader context of chloracne claims. The Repatriation Medical Authority's determinations have been challenged in the past on grounds including that the Authority failed to consider relevant scientific evidence or that the factors are too restrictive, but no such challenges are recorded in this instrument. The instrument's silence on litigation does not mean no litigation exists; it simply means the instrument does not reference any. Users of this deep dive should be aware that administrative decisions applying this instrument are reviewable, and the Federal Court has developed a body of case law on the meaning of "reasonable hypothesis" and the weight to be given to Statements of Principles generally. The absence of cited cases in the instrument is typical for such instruments, which are drafted as self-contained medical-scientific standards. The instrument is likely to be cited in litigation concerning chloracne claims, but the instrument itself does not record that fact.

Several features of this Statement of Principles could catch out claimants and practitioners. The first is the narrow definition of chloracne. It characterises the disease as occurring after systemic absorption of "certain polyhalogenated aromatic hydrocarbons", but the definition is tightly limited to the specific list in the dictionary. A person who develops an acne-like rash after exposure to a chloracnegenic compound that is not on the list, such as a newer brominated flame retardant or a mixture that is not exactly one of the named congeners, will not satisfy the definition. The list is exhaustive. Second, the temporal window is three months before the clinical onset or worsening. This is short relative to the latent period for some chloracne cases, which can be months or even years after exposure. If the exposure occurred more than three months before the onset, the factor is not satisfied even if the exposure is the clear cause, unless the person can show continuous or repeated exposure within that window. Third, the instrument includes a factor for inability to obtain appropriate clinical management, but "inability" is not defined. This may be difficult to establish if the person had access to medical care but chose not to use it, or if the treatment was ineffective. Fourth, the note to factor 9(1) lists examples of products and circumstances, but these are illustrative only. A claimant cannot rely on these examples as exhaustive; they must point to actual exposure to a listed hydrocarbon. Fifth, the instrument excludes drug-related acneiform facial eruptions. If a veteran's skin condition is caused by a medication, it is not chloracne for the purposes of this SOP, even if the medication is a halogenated compound. Sixth, the relationship to service provisions in section 10 require that the factor be related to relevant service. For factor 9(2) (worsening) and 9(3) (inability to obtain appropriate management), the person's chloracne must have been suffered or contracted before or during (but did not arise out of) relevant service. This means that if chloracne first arose during service, it cannot be worsened by service; only pre-service chloracne can be aggravated. Seventh, the cross-reference in section 11 means that if a factor in section 9 refers to another disease (for example, if exposure to PCBs caused liver damage and the liver damage then contributed to chloracne), the SOP for that other disease must also be satisfied, potentially creating a multi-step chain of proof.

Compliance with this instrument is not about following a set of rules; it is about satisfying the evidentiary requirements for a compensation claim. For a claimant seeking to have chloracne accepted as service-related, the first step is to obtain a medical diagnosis that meets the definition in subsection 7(2). The diagnosis must confirm that the condition is chloracne and not a drug-related acneiform eruption. The second step is to identify which factor or factors under section 9 apply. Most commonly this will be factor 9(1) or 9(2) concerning exposure to a polyhalogenated aromatic hydrocarbon. The claimant must demonstrate that within the three months before the clinical onset (or worsening) of chloracne, they inhaled, ingested, or had cutaneous contact with a substance that is on the specified list. This requires evidence of the specific chemical and the route of exposure. The notes to factor 9 give examples of products (fungicides, herbicides, insecticides, transformer oils, wood protectors) and circumstances (being in dust from treated timber, being sprayed, cleaning equipment, consuming contaminated cooking oil, decanting or spraying, handling saw timber, using contaminated cutting oil). The claimant should gather documentary evidence such as service records, workplace incident reports, material safety data sheets, and any contemporaneous medical records that describe the exposure. If the exposure was to a mixture containing multiple listed substances, the claimant must identify at least one that is on the list. The third step is to establish that the factor is related to relevant service. This means that the exposure must have occurred during service that qualifies as operational, peacekeeping, hazardous, British nuclear test defence, warlike, or non-warlike service. Standard service records should show this. The fourth step is to rule out factor 9(3) (inability to obtain appropriate clinical management) if that is not the basis of the claim, but it may be a fallback. If the claimant cannot prove exposure within three months, factor 9(3) may be available if they can show that they could not obtain appropriate clinical management for chloracne after onset. That might apply if medical care was unavailable in a remote posting or if the condition was misdiagnosed. For decision-makers, compliance means strictly applying the factors as written. They should not accept a claim if the chemical is not on the specified list, even if it is chemically similar. They must confirm the temporal window and ensure that for worsening claims, the chloracne was pre-existing. They must also apply section 11 if any factor triggers another SOP. Legal practitioners advising claimants should obtain expert medical evidence that addresses the specific chemical and the timing, and should be prepared to challenge any decision that ignores a plausible factor. The burden of proof for a reasonable hypothesis is lower than that for balance of probabilities, but it is not satisfied by mere speculation. The instrument therefore demands concrete evidence of exposure, not just a possible link.